Future Treatment Options for Multiple Myeloma

  Amrita Krishnan, MD, hematologist-oncologist at the City of Hope Comprehensive Cancer Center, talks about what the future holds for managing people with multiple myeloma. Multiple myeloma is a rare hematologic cancer characterized by the expansion of malignant...

Risdiplam and Spinal Muscular Atrophy

  Claudio Santos, MD, MBA of PTC Therapeutics provides an update on the orphan drug being developed by the company, in partnership with Roche, to treat spinal muscular atrophy (SMA). The drug, risdiplam, is a  survival motor neuron-2 (SMN2) splicing modifier...

Gene Therapy and Hemophilia A

  Adrian Woolfson, MD, PhD, of Sangamo Therapeutics talks about the physical and psychological advantages of using gene therapy to treat hemophilia A. Hemophilia A is a genetic blood disorder caused by a missing or defective factor VIII. Symptoms are dependent on...

Why Joint Pain Is Common in Hemophilia

  Gallia Levy, MD, PhD, Associate Group Medical Director, at Genentech explains why joint pain is so prevalent in persons with Hemophilia A. Hemophilia A is a genetic disorder caused by missing or defective clotting protein, factor VIII. Symptoms are dependent on...

Programmed Cell Death Following Hemorrhagic Stroke

  Rajiv Ratan, MD, PhD, of the Burke Neurological Institute, explains the mechanisms involved in how cells undergo ‘programmed death’ following a hemorrhagic stroke. A hemorrhagic stroke occurs when a blood vessel bursts and blood leaks into the surrounding brain...
  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.